Prader-Willi experts flag safety risks linked to Neurocrine's rare disease drug - Reuters
Prader-Willi experts flag safety risks linked to Neurocrine's rare disease drug Reuters
Coverage by Political Leaning
See how different sides of the spectrum reported this story
Key People
No people linked to this story
Locations
Tags
All Coverage
<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxOUHpjZ3JJLW02dWN5c1Z3N1hXUExHN1czcGxvRnR0bEQ4WHp0YzFOWlQ2Y193UmxNcl9BLTJHbnFDd0VpUS1INDN6d1EyYnFBUFlGaTJlOUFlUG5HWDA0ZE05dk9NVlEtQmlCazhJQlY2UVByZ1B2R3ZJZEJ4VHFGV3FLNmE0MTVBNk1EMGV5X3ZGRG5NbkR3SnZ0RmtURTRxSDMya3g5VEpybzF2ZzIxa3cyaDR3d3RuV3k3V2xGWVk2YzVraHYw?oc=5" target="_blank">Prader-Willi experts flag safety risks linked to Neurocrine's rare disease drug</a> <font color="#6f6f6f">Reuters</font>
Similar Stories
Related coverage based on topic and tags
US FDA approves AbbVie's drug for Parkinson's disease - reuters.com
US FDA approves AbbVie's drug for Parkinson's disease reuters.com
September 25, 2026 at 10:57 PMUS FDA extends review of Novo Nordisk's hemophilia drug over facility issues - Reuters
US FDA extends review of Novo Nordisk's hemophilia drug over facility issues Reuters
October 2, 2026 at 09:52 PMExperimental Lilly combination drug tops Zepbound in weight-loss trial - Reuters
Experimental Lilly combination drug tops Zepbound in weight-loss trial Reuters
September 30, 2026 at 05:34 PMUniQure plunges as Huntington's trial data disappoints investors - reuters.com
UniQure plunges as Huntington's trial data disappoints investors reuters.com
September 29, 2026 at 10:11 PMLilly's experimental drug cuts weight by 21% in diabetes trial - reuters.com
Lilly's experimental drug cuts weight by 21% in diabetes trial reuters.com
September 29, 2026 at 10:15 PMNovo says Ozempic shows lower risk of cardiovascular events compared to Lilly's Mounjaro - reuters.com
Novo says Ozempic shows lower risk of cardiovascular events compared to Lilly's Mounjaro reuters.com
September 29, 2026 at 09:49 PM